By Amy Norton
MONDAY, April 1 (HealthDay News) -- Many people who quit taking their cholesterol-lowering statin drugs because of side effects can successfully try again, a new study suggests.
Researchers found that of more than 100,000 Boston-area adults who started a statin drug, 17 percent stopped taking it because of side effects -- most often, muscle aches. But within a year, more than half gave statins another chance, and most -- 90 percent -- were able to stick with it.
Experts said the findings, reported in the April 2 issue of the journal Annals of Internal Medicine, show that people need not abandon statins if a potential side effect crops up.
In some cases, the problem may not be caused by the drug at all, said senior researcher Dr. Alexander Turchin, of Brigham and Women's Hospital in Boston.
"Muscle pain can happen with statins," he said, "but it can also have many other causes."
In other cases, Turchin said, people are having a real side effect, but might do better with a lower dose or with a different statin.
"There are some people who simply cannot tolerate statins," Turchin said. "But in most cases, it's worth trying again."
A cardiologist not involved in the study agreed. "Just because you have a side effect doesn't mean you have to stop statins forever," said Dr. Tara Narula, associate director of the cardiac care unit at Lenox Hill Hospital in New York City.
If you think you're having a side effect, Narula said, you should talk to your doctor about it and not just stop the statin on your own. Your doctor will probably have you stop taking the drug for a couple weeks to see if the symptoms go away.
In the United States, about one-quarter of adults older than 45 are on statins, which include drugs such as simvastatin (Zocor), atorvastatin (Lipitor) and lovastatin (Mevacor). They are used to cut "bad" LDL cholesterol and help prevent heart disease, and run anywhere from around $10 to a few hundred dollars per month, depending on whether it's a generic or brand name.
The new findings are based on medical records for nearly 108,000 patients who started a statin between 2000 and 2008. When they stopped due to a side effect, the most common reason was muscle aches and pain, followed by other "musculoskeletal" problems such as joint pain or muscle spasms.
Doctors, as well as many patients, know that muscle pain is a potential statin side effect, so they may be quick to suspect the drug when aches arise, Narula noted.
"It's obviously important to listen to patients and take their complaints seriously," Narula said. But, she added, the problem comes when patients are taken off the statin and "the issue is never addressed again."
Besides muscle and joint problems, other statin side effects include nausea, diarrhea and constipation. More serious problems have been reported -- such as liver damage and a dangerous breakdown of the muscle called rhabdomyolysis -- but they are rare.
Statins have also been linked to an increased risk of type 2 diabetes, and to reports of memory problems in some users, according to the U.S. Food and Drug Administration. But it's not clear that the drugs are to blame.
Turchin said memory loss was reported for only 0.06 percent of patients in his study. "It was very uncommon in this group," he said.
Of all study patients who stopped their statin use due to side effects, nearly 60 percent tried again -- either the same statin or a different one. It's not clear why the other 40 percent did not.
"Maybe the patient didn't want to," Turchin said. "Or maybe the doctor didn't offer."
There are other ways to rein in high cholesterol. If LDL is moderately high, diet changes, exercise and shedding excess pounds may be enough. But for people who are at high risk of a heart attack -- because of past heart problems or conditions like diabetes -- doctors typically prescribe a statin right away.
It's estimated that about 5 percent to 10 percent of patients are truly "statin intolerant," said Dr. Scott Grundy, who wrote an editorial published with the study. If those patients are able to go back on a statin, it's often at a dose that doesn't cut LDL by much, said Grundy, of the University of Texas Southwestern Medical Center in Dallas.
But other types of cholesterol drugs might help, he added.
The study was funded by government and private grants. Turchin has received research funds from Merck, which makes Zocor and Mevacor.